Emerging biopharma companies preparing for their first product launch face the challenge of demonstrating early revenue growth and a clear path to profitability while operating with limited budgets, regulatory uncertainty, and minimal margin for error. These pressures are especially significant in rare disease markets, where traditional launch models are often costly, complex, and resource-intensive for inexperienced launch teams. To address these challenges, EVERSANA developed EVERSANA COMPLETE Commercialization®, offering emerging biopharma organizations a more flexible and effective commercialization approach. In a recent rare disease launch, one company faced a critical strategic decision: how to bring its product to market while preserving long-term value, maintaining ownership and co

Join for free to read